https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/
Roche, trailing in obesity, showcases new data for GLP-1 shot | BioPharma Dive
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.
new datarochetrailingobesity
https://endpoints.news/wave-life-sciences-says-its-rna-obesity-shot-cuts-fat-but-retains-muscle/
Updated: Wave Life Sciences’ RNA obesity shot cuts fat and retains muscle, but appears to lag...
wave lifeobesity shotupdated
https://endpoints.news/innovent-to-seek-china-approval-of-high-dose-obesity-shot-after-phase-3-hit/
Innovent to seek China approval of high-dose obesity shot after Phase 3 hit
Nov 20, 2025 - Innovent Biologics' obesity drug Xinermei (mazdutide) at 9mg weekly dose led to 18.6% weight loss in China-based Phase 3 trial; company to seek higher dose...
obesity shotinnoventseekchina